Metronidazole improves intestinal microcirculation in septic rats independently of bacterial burden

Area of Science:

• Pharmacology
• Microcirculation Research
• Sepsis Pathophysiology

Background:

• Sepsis significantly impairs intestinal microcirculation, affecting nutrient and oxygen delivery.
• Intestinal microcirculatory dysfunction is a critical factor in sepsis-induced organ damage.
• Metronidazole (Me) is an antibiotic with potential anti-inflammatory properties.

Purpose of the Study:

• To investigate the effects of metronidazole (Me) on intestinal microcirculation in rat models of sepsis.
• To differentiate the direct effects of Me on microcirculation from its antibacterial actions.
• To assess Me's impact on functional capillary density and leukocyte-endothelial interactions.

Main Methods:

• Intravital microscopy (IVM) was used to examine intestinal microcirculation in two rat models: colon ascendens stent peritonitis (CASP) and lipopolysaccharide (LPS) challenge.
• Animals were studied in control and treatment groups, with and without Me (10 mg/kg i.v. for CASP, 15 mg/kg i.v. for LPS).
• Key parameters assessed included functional capillary density (FCD) and leukocyte sticking in V1 venules.

Main Results:

• Metronidazole treatment significantly improved functional capillary density (FCD) in the intestinal wall of both CASP and LPS models compared to untreated groups.
• Me treatment significantly reduced the increased adherence of leukocytes to the endothelium (leukocyte sticking) in the submucosal venules.
• These improvements were observed independently of the antibacterial effects, suggesting direct microcirculatory benefits.

Conclusions:

• Metronidazole demonstrates beneficial effects on intestinal microcirculation during sepsis.
• Me reduces leukocyte sticking and improves capillary blood flow, mitigating inflammatory responses.
• The study concludes that metronidazole possesses both anti-bacterial and anti-inflammatory effects relevant to septic microcirculation.